The chemical class referred to as Vmn2r33 Activators encompasses a range of compounds that can play a role in modulating the activity of the Vmn2r33 receptor, which is a member of the G protein-coupled receptors (GPCRs). These activators are not direct ligands for the receptor but can influence its activity through various indirect mechanisms within the cellular signaling framework. Their actions can result in altered intracellular concentrations of second messengers such as cyclic adenosine monophosphate (cAMP) or intracellular calcium, which in turn can affect the signaling state of Vmn2r33. Some activators work by stimulating enzymes like adenylyl cyclase to increase cAMP production, while others may inhibit the breakdown of cAMP, thereby sustaining its signaling effect. There are also activators that influence the receptor's activity through modulation of protein kinase C (PKC) or by altering the dynamics of calcium ions within the cell, which are crucial secondary messengers in GPCR signaling pathways.
The mechanisms by which these activators function involve complex interactions and cascades that are central to GPCR signaling. For instance, changes in cAMP levels can result from the activation of adenylyl cyclase or inhibition of phosphodiesterases, leading to a sequence of events that affect the receptor's signaling state. Similarly, the manipulation of intracellular calcium levels can initiate a series of downstream effects, influencing various kinases and other signaling molecules. Activators that modulate these pathways can therefore indirectly modulate the activity of Vmn2r33. Furthermore, some activators may alter the signaling milieu through the inhibition of specific enzymes like phospholipase C, or by affecting the function of ion channels, thereby contributing to the overall regulatory landscape of Vmn2r33 activity. These compounds, by acting on various components of the GPCR signaling network, can modulate the activity of Vmn2r33 and its associated pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, increasing cAMP by preventing its degradation, which could possibly activate Vmn2r33 by amplifying GPCR-mediated signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activator of protein kinase C (PKC) which could phosphorylate downstream targets within the GPCR pathway, and could possibly activate Vmn2r33. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium levels, which could possibly activate Vmn2r33 by activating secondary signaling cascades involved in GPCR signaling. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, which could lead to increased cAMP by disinhibition of adenylyl cyclase, and could possibly activate Vmn2r33 signaling. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), which could influence intracellular signaling pathways downstream of GPCRs, and could possibly activate Vmn2r33. | ||||||
Nitrendipine | 39562-70-4 | sc-201466 sc-201466A sc-201466B | 50 mg 100 mg 500 mg | $109.00 $160.00 $458.00 | 6 | |
L-type calcium channel blocker that can modulate calcium signaling pathways, and could possibly activate Vmn2r33 GPCR activity. | ||||||
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | $122.00 $281.00 $388.00 $683.00 $1428.00 $3060.00 | 12 | |
Mimics acetylcholine, activating cholinergic receptors that can modulate GPCR signaling, and could possibly activate Vmn2r33 through cross-talk between pathways. | ||||||